Expression and function of the oncogenic transcription factor activator protein (AP-
Introduction
Cancer is a multistage disorder in which genetic and epigenetic changes result in characteristic alterations within the gene regulatory network and, thereby, influence the cellular decision of differentiation, proliferation, or survival (1) . Regulation of gene transcription is a process that is primarily under the influence of nuclear-located transcription factors that exhibit tightly controlled DNA-binding as well as physical and functional interactions with transcriptional coregulators. Consequently, identifying transcription factors that activate or repress specific target genes is a prerequisite for understanding cell fate and function during neoplastic transformation.
Much of our current knowledge about the characteristics of transcription factors comes from the discovery and study of activator protein 1 (AP-1; ref.
2). AP-1 describes an activity that controls both basal and inducible transcription of target genes sharing AP-1 binding sites, also known as 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive element (TRE), within their genomic regulatory regions (3) . AP-1 is mainly composed of Jun and Fos proteins that form homodimers (Jun-Jun) and heterodimers (Jun-Fos) and mediates gene transcription in response to a plethora of stimuli (4) . Studies in genetically modified mice and cells derived thereof have highlighted a crucial role for AP-1 in a variety of cellular events implicated in normal development as well as in pathologic conditions, including cancer. As an example, expression of a dominant-negative Jun mutant (TAM67) in basal keratinocytes protects transgenic mice from UV-and chemically induced as well as human papillomavirus 16-driven skin tumor formation (5, 6) . Additionally, mice harboring a mutant Jun allele that has the Jun-NH 2 -kinase phospho-acceptor serines changed to alanines as well as mice with an epidermal-specific Jun knockout (Jun Dep ) exhibit impaired skin tumor development in the K5-SOS-F transgenic tumor model (4) . The important role of AP-1 for malignant transformation of keratinocytes is further supported by the fact that Fos-deficient mice fail to undergo malignant progression of skin tumors in a transgenic model of oncogenic Ras (7) . Finally, the conditional expression of A-Fos, a dominant negative mutant that inhibits AP-1 DNA-binding, in epidermal keratinocytes of transgenic mice interferes with the development of characteristic benign or malignant squamous cell lesions during chemically induced skin carcinogenesis (8) .
In this study, we used the tumor-prone K5-SOS-F transgenic mouse model to screen systematically for novel Fos-regulated genes performing global gene expression analysis with samples derived from skin tumors with a floxed Fos allele (Fos f/f ) or with an epidermis-specific Fos-deletion (Fos Dep ). We could identify a comprehensive list of differentially expressed genes and confirmed Fos-dependent expression of selected genes in TPA-treated back skin. In line with published data that Fos induces epithelialmesenchymal transition in vitro and is critical for malignant progression in vivo (7, 9) , numerous differentially expressed genes were functionally associated with cellular movement and cell morphology. We found that the mucin-like glycoprotein Podoplanin (Pdpn), one of the highest differentially expressed genes, is a novel direct Fos target gene. Previously, Pdpn was found significantly up-regulated in advanced stages of the two-step skin carcinogenesis (10) as well as in human cancer, including squamous cell carcinomas of the skin (11, 12) . Additionally, ectopic
Pdpn expression accelerates cell motility and invasion in vitro, is sufficient to induce tumor growth in a xenograft model, and induces tumor cell invasion and metastasis in vivo (12, 13 
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À/À , and JunB À/À embryos as described previously (18, 19) .
Serum-starved cells were treated with 100 ng/mL TPA dissolved in acetone for the indicated time points. Immortalized mouse keratinocytes (IMK) were established as described elsewhere (20) .
Tissue preparation and immunohistochemistry analysis. For immunohistochemistry (IHC) staining, skin and tumor samples were fixed in 4% w/v paraformaldehyde [PFA in PBS (pH 7.2)], embedded in paraffin, and subsequently cut in 6-Am sections. IHC stainings were done with the Immunodetection kit (Vector Laboratories) according to manufacturer's instructions. Primary and secondary antibodies used in this manuscript are listed in Supplementary Table S2 .
Chromatin immunoprecipitation analysis. For chromatin immunoprecipitation (ChIP) analysis, the ChIP assay kit (Upstate Biotechnology) was used following the manufacturer's instructions. The ChIP experiment was performed with IMKs treated for 1 or 2 h with 100 ng/mL of TPA or for 2 h with acetone as control. Cross-linked Fos protein-DNA complexes were immunoprecipitated with a Fos-specific antibody (Supplementary Table S2 ). PCR amplification of the immunoprecipitated samples was performed using primers located within the proximal Pdpn promoter (Supplementary Table  S3 ). Immunoprecipitates in the absence of antibody and a portion of the sonicated chromatin before immunoprecipitation were used as controls. A PCR using a primer-pair specific for a b-Tubulin coding region (Supplementary Table S3 ) served as an additional control.
Transfection and reporter gene assay. The mouse proximal Pdpn promoter was amplified by PCR (see Supplementary Table S3 for primer sequences) and cloned in the pGEM-T easy plasmid (Promega). A 327-bp fragment was isolated by HindIII and NcoI digestion and cloned into the pGL3-basic vector (Promega) to generate the Pdpn-luci(À215/+113) reporter plasmid. The Pdpn-luci(À860/+113) reporter plasmid was generated by insertion of a 625-bp fragment (XhoI/HindII) of the pGEM-T easy clone into the Pdpn-luci(À215/+113) reporter plasmid. Both constructs were approved by DNA sequencing. MEFs were transiently transfected with reporter gene plasmids using FuGENE HD Transfection Reagent according to the manufacturer's instructions (Roche). A Renilla luciferase reporter gene plasmid was cotransfected as an internal control for transfection efficiency (Promega). Cells were harvested 48 h after transfection, and the measurement was performed using the Dual Luciferase Assay System (Promega). To calculate fold inductions, the relative light units of mock-transfected cells were set to 1. All values are means of at least three independent experiments and error bars represent SE. The TRE-luci reporter plasmid and the Fos expression plasmid were described previously (21) .
Nuclear extracts, EMSA, and Western blot analysis. Isolation of nuclear extracts, electrophoretic mobility shift assay (EMSA), and Western Blot analysis were performed as described previously (22) . Oligonucleotides for the TRE-Coll probe were described by Porte and colleagues (23) , oligonucleotides of the Pdpn promoter are listed in Supplementary Table S3 , and oligonucleotides for the Oct probe were kindly provided by T. Wirth (University of Ulm, Ulm, Germany). Antibodies for Western Blot are listed in Supplementary Table S2 .
Microarrays, sample preparation and hybridization, quantitative real-time PCR analysis, and data processing. See Supplementary Materials and Methods.
Results and Discussion
Identification of Fos-regulated genes in the K5-SOS-F tumor model. We crossbred tumor-prone K5-SOS-F mice with genetically modified animals containing either floxed c-Fos alleles (Fos f/f SOS + ) or an epidermis specific c-Fos deletion (Fos Dep SOS + ). As expected, Fos f/f SOS + mice developed highly disorganized papillomatous lesions within 4 weeks after birth. In the absence of Fos, tumor volume was significantly reduced, supporting the crucial role of Fos expression and activity for neoplastic transformation of epidermal keratinocytes. 4 To identify tumor-associated genes whose expression critically depends on the presence of Fos function, we isolated total RNA from tumor samples of three independent Table S1 ). Numerous differentially expressed genes of the list were previously identified as tumor-associated genes in the two-step skin carcinogenesis model (24) (25) (26) . Gene clustering according to their functional annotation showed that differentially expressed genes are implicated in distinct tumorigenic features, such as cellular movement and morphology, cell cycle control and proliferation, cell death, cell signaling, and interaction (Fig. 1) .
We selected several up-regulated genes (Fetub, Klk12, Mmp10, Pdpn, and Ptgs2) and one down-regulated gene (S100a3) for quantitative real-time PCR (RQ-PCR) analysis and could confirm altered transcription in Fos f/f SOS + compared with Fos Dep SOS + samples ( Fig. 2A) . Most of the analyzed genes also exhibited TPAinduced transcription in mouse back skin, which was impaired in Fos-deficient animals. Additionally, costimulation with dexamethasone, a well-known inhibitor of Fos-dependent transcription, repressed TPA-induced Klk12 and Pdpn expression (Fig. 2B ). Efforts to highlight the role of AP-1 family members in neoplastic transformation often focus on enhanced gene transcription; however, recent experimental data also suggest a contribution of transcriptional repression in Fos-mediated cellular transformation (27) . We found several candidate genes with significantly higher transcript levels in the absence of Fos protein, and as an example, we analyzed Fos-dependent regulation of S100a3 transcription. In wt mice, S100a3 transcript levels were dramatically reduced in TPA-treated compared with acetone-treated skin (33-fold; Fig. 2B ). Although basal S100a3 transcription was slightly reduced in Fos À/À compared with wt skin (2-fold), we found no further downregulation after TPA treatment, suggesting that Fos function is essential for the repression of S100a3 transcription.
Fos-dependent Pdpn expression in skin tumors. One gene that was highly reduced in Fos
Dep SOS + compared with Fos f/f SOS tumors and whose TPA-induced transcription in mouse skin critically depends on Fos (Fig. 2) (Fig. 3A) . Additionally, we found Pdpn and Fos-positive tumor cells in the same area of consecutive sections derived from the two-step skin carcinogenesis model (Fig. 3B) . Our data are in line with previous publications and support the hypothesis that Pdpn expression may be modulated by the tumor environment and is induced in epithelial cells by growth factors and cytokines secreted from cells within the tumor stroma (12) .
Pdpn is a direct Fos target gene. IHC analysis revealed enhanced Pdpn protein expression in epidermal keratinocytes as well as dermal fibroblasts of TPA-treated skin ( Supplementary  Fig. S1 ). To confirm TPA-induced Pdpn transcription in both cell types, we generated IMKs and used established MEFs (Fig. 3C) . In contrast to IMKs and control MEFs, no up-regulation of Pdpn transcripts was detected in cells derived from Fos-deficient embryos. To investigate whether Fos directly binds to the Pdpn promoter, MEF and IMK cells were treated with TPA to induce endogenous Fos protein expression followed by ChIP with a Fosspecific antibody. PCR analysis using primers that amplify the proximal Pdpn promoter revealed direct Fos DNA binding 2 hours after TPA stimulation of IMK cells but not in control-treated cells or after 1 h of treatment ( Fig. 4A; Supplementary Fig. S2 ). Enrichment of Pdpn promoter sequences in ChIP experiments with TPA-treated IMK cells could be confirmed by RQ-PCR analysis and was also detected in wt MEFs upon TPA stimulation but not in Fos À/À MEFs (data not shown).
Several TRE-like motifs were present in the proximal Pdpn promoter and downstream of the transcription start site. Therefore, we cloned two Firefly-luciferase reporter gene plasmids, Pdpnluci(À215/+113) and Pdpn-luci(À860/+113), to analyze Pdpn promoter activity in wt and Fos À/À MEFs. Transient transfection experiments revealed basal activity of both promoter constructs in wt MEFs that was significantly enhanced by TPA treatment ( Fig.  4B ; data not shown). In line with Fos-dependent Pdpn transcription in vitro and in vivo, we found that both basal and induced promoter activity was impaired in the absence of Fos ( Fig. 4B ; data not shown). Because similar data were obtained with the Pdpn-luci(À860/+113) and the Pdpn-luci(À215/+113) reporter plasmid, the latter was used to confirm induced Pdpn transcription upon ectopic Fos expression. Cotransfection with Pdpn-luci(À215/ +113) reporter and a Fos expression plasmid revealed a 3.6-fold induction in wt and a 2.6-fold induction in Fos À/À MEFs (Fig. 4C ),
demonstrating that ectopic Fos expression is sufficient to induce Pdpn transcription. To identify the TRE-like motif that is required for Fos binding to the Pdpn promoter, we performed EMSA experiments with distinct radioactive-labeled oligonucleotides covering the critical genomic region. An inducible bandshift was detected with nuclear extracts of TPA-treated MEFs and IMKs ( Fig. 4D ; Supplementary  Fig. S3 ), and the respective oligonucleotide (PdpnIV) shares a TRE-like binding motif. Indeed, we found a complete loss of TPAinduced complex formation upon introduction of specific mutations (PdpnIV-mut1 and PdpnIV-mut2) as well as impaired binding by competition with nonlabeled oligonucleotides with a conserved TRE motif (Supplementary Fig. S3 ). In line with our ChIP assay, EMSA analysis showed enhanced complex formation at the PdpnIV oligonucleotide with nuclear extracts from HeLa cells that were transiently transfected with a Fos-expression plasmid compared with mock controls (Supplementary Fig. S3 ). Fig. S2 ), suggesting a regulation by functional JunFos heterodimers. In summary, global gene expression analysis and the systematic analysis of a Fos-dependent genetic pattern using a wellestablished mouse model of skin carcinogenesis revealed a comprehensive list of well-known Fos/AP-1 target genes but also novel candidates. Further analysis of these genes concerning their promoter topology and biological function will certainly contribute to a better understanding of AP-1 mediated gene regulation and molecular principles of Fos-driven cellular transformation. Accordingly, we identified Pdpn as a novel direct Fos target gene in both fibroblasts and keratinocytes. Pdpn and Fos proteins are critically implicated in epithelial cell migration and invasion in vitro and closely correlated with malignant progression in vivo. Moreover, investigating cell lines with inducible Fos expression and a Fos-transgenic mouse model that develops bone tumors (28), 
